Reaction
Giant Cell Arteritis reporting signals
As of the last recalculation, Giant Cell Arteritis appears in 797 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is TOCILIZUMAB (PRR 48.8).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Tocilizumab | 169 | 48.8 | 48.9 |
| Zoledronic Acid | 40 | 27.3 | 27.4 |
| Desloratadine | 11 | 27.1 | 27.2 |
| Telmisartan | 16 | 23.9 | 23.9 |
| Baricitinib | 5 | 13.6 | 13.6 |
| Ipilimumab | 20 | 12.4 | 12.4 |
| Upadacitinib | 34 | 11.3 | 11.3 |
| Ranolazine | 4 | 10.1 | 10.1 |
| Bendamustine Hydrochloride | 4 | 8.8 | 8.8 |
| Ranibizumab | 8 | 7.9 | 7.9 |
| Romosozumab-Aqqg | 4 | 7.7 | 7.7 |
| Rimegepant Sulfate | 3 | 6.2 | 6.2 |
| Abaloparatide | 6 | 5.4 | 5.4 |
| Aflibercept | 6 | 5.1 | 5.1 |
| Sarilumab | 5 | 5.0 | 5.0 |